1. Home
  2. UEIC vs NXTC Comparison

UEIC vs NXTC Comparison

Compare UEIC & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Electronics Inc.

UEIC

Universal Electronics Inc.

HOLD

Current Price

$3.99

Market Cap

48.3M

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$11.10

Market Cap

49.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UEIC
NXTC
Founded
1986
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.3M
49.0M
IPO Year
1993
2019

Fundamental Metrics

Financial Performance
Metric
UEIC
NXTC
Price
$3.99
$11.10
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$9.25
$23.00
AVG Volume (30 Days)
62.2K
26.5K
Earning Date
02-19-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$390,997,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.35
N/A
52 Week Low
$2.69
$2.69
52 Week High
$10.34
$15.74

Technical Indicators

Market Signals
Indicator
UEIC
NXTC
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
UEIC
NXTC

About UEIC Universal Electronics Inc.

Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: